Učitavanje...
Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural factors. Selexipag is a recently approve...
Spremljeno u:
| Izdano u: | Pulm Circ |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681254/ https://ncbi.nlm.nih.gov/pubmed/31215322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019862167 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|